Skip to content
Review

Atrial Fibrillation Burden as an Outcome in Clinical Trials.

Oct 2026 · NEJM Evidence · Vol 5 11, pp. EVIDctw2600179 · 0 citations · 27 references
Medicine

TL;DR

The role of atrial fibrillation burden as a primary outcome for atrial fibrillation intervention trials is evaluated and key considerations for ascertainment, definition, and analysis of atrial fibrillation burden are evaluated.

Abstract

AbstractAtrial fibrillation is the most common cardiac arrhythmia in the world. In clinical trials evaluating interventions for atrial fibrillation, outcomes have been traditionally defined using a thirty second arrhythmia end point. In this Clinical Trials Workshop, we evaluate the role of atrial fibrillation burden as a primary outcome for atrial fibrillation intervention trials. In particular, we evaluate key considerations for ascertainment, definition, and analysis of atrial fibrillation burden while further considering regulatory implications of its use as a primary end point.

View source

Similar papers

Open access Oct 2026

Heart Failure Progression in the Setting of Persistent Atrial Fibrillation, Frequent Premature Ventricular Complexes, and Malignancy‐Related Limitations to Guideline‐Directed Medical Therapy: A Case Report

In patients with progressive ventricular dysfunction and limited pharmacologic options, atrioventricular nodal ablation with cardiac resynchronization therapy‐defibrillator implantation may provide durable rate control and support subsequent ventricular functional recovery.

Douni Roger, W. Shaker, Majid Yavari et al. · 0 citations
Review Open access Nov 2026

Controversy: Atrial fibrillation ablation should be performed in patients with HFpEF.

The role of atrial fibrillation (AF) ablation in the management of heart failure with preserved ejection fraction (HFpEF) remains an under investigated issue with no robust clinical trials data. This controversy reviews the evidence for and against AF ablation in this complex condition from two different perspectives r...

L. di Biase, Carolyn S. P. Lam, Feng-Wei Zou et al. · 0 citations
Review Open access Oct 2026

Beyond Atrial Fibrillation: Clinical and Echocardiographic Predictors of Ischaemic Stroke and Systemic Thromboembolism in Rheumatic Heart Disease: A Systematic Review and Meta‐Analysis

Atrial fibrillation (AF) is the best‐established thromboembolic risk factor in rheumatic heart disease (RHD), but stroke and thromboembolism also occur without documented AF. We systematically synthesised associations between non‐AF clinical/echocardiographic predictors and thromboembolism in RHD, comparing AF‐adjusted...

Naveen Baby, Nishanth Gowda, H. Neha · 0 citations
Open access 2021

Atrial Fibrillation: Stroke and bleeding Risk Assessment

Atrial fibrillation increases with increased elderly population and it increases the risk of thromboembolism that may lead to stroke. Both CHADS2 and CHA2DS2 VAS scores are widely used to assess the stroke risk according to current international guidelines. The accuracy of both scores in predicting stroke risk is only...

H. Ismail, H. Yamany, Hassan A Shora · 0 citations
Open access Oct 2026

Longitudinal Left Atrial Remodeling With Pharmacological Rhythm Versus Rate Control in Paroxysmal and Persistent Atrial Fibrillation

Evidence regarding left atrial (LA) remodeling with pharmacological rhythm control remains limited, particularly in patients with atrial fibrillation (AF) outside heart‐failure‐specific populations.

S. Chien, Chih-Hui Chin, Chao-Chien Chang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.